Aptamer Group has launched its biomarker discovery service, offering researchers in pharmaceutical, biotechnology, and diagnostic development a new approach to identify and validate new disease markers. The service integrates Aptamer’s Optimer technology with proteomic analysis to provide an unbiased, high-throughput approach to biomarker identification. This… Read More
Aptamer Group and AstraZeneca have entered a collaboration agreement to evaluate Aptamer’s Optimer fibrotic liver delivery vehicles for the targeted delivery of small interfering RNA (siRNA). Following the encouraging results achieved to-date with Aptamer’s fibrotic liver delivery vehicles, the next phase of the research will… Read More
From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did… Read More
Biopharmaceutical company Basking Biosciences has revealed positive Phase I study results for its reversible thrombolytic therapeutic for ischaemic stroke. The company’s novel von Willebrand Factor (vWF)-targeting thrombolytic agent, BB-031 demonstrated safety and tolerability following a single intravenous dose. The study results were presented at the… Read More
Ixaka and SomaLogic have created a research collaboration to support the development of aptamer-based bispecific therapeutics. The collaboration will evaluate the safety and efficacy of antigen-specific SOMAmer reagents (modified aptamers that bind tightly and specifically to protein targets) previously identified and screened by SomaLogic as potential candidates for combination with… Read More
